Recent Initiation of Testosterone Therapy Linked to Greater Atherosclerosis Progression in MSM With HIV
New findings contribute to the indication that people with HIV taking testosterone therapy should be counseled on the cardiovascular risks.
With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.
Dec. 19, 2019: Often-insufficient CD4 and viral load testing for women; factors affecting syphilis incidence among women with HIV; STI testing rates among people with HIV; the effect of benzodiazepines on neurocognition.
Dec. 5, 2019: The value of pre-treatment drug resistance testing; resistance rates among viremic Americans; persistent pneumonia incidence among people with HIV; mixed HIV prevention results for the U.S. National HIV Strategy.
The vaccine for human papillomavirus got a bad rap when it debuted. And yet time has shown it's very effective in reducing cancers linked to HPV.
A series of studies aim to determine whether test-and-treat strategies can be implemented for people with hepatitis C, much like programs for people living with HIV.
Sept. 26, 2019: Racial disparities in the PrEP continuum; HIV and ocular syphilis; Kaposi sarcoma among people with well-suppressed HIV; modifiable risk factors in the management of chronic kidney disease.
A new study adds to mounting evidence that all people should be screened and offered the vaccine for human papillomavirus.
Aug. 29, 2019: Viral load blips, low-level viremia, and eventual virologic failure; pinpointing non-adherence as a cause of HIV treatment failure; HIV care costs vary widely throughout U.S.; Kaposi sarcoma incidence in the modern HIV treatment era.
Aug. 8, 2019: Casual sex partners increase among U.S. MSM; why some MSM undervalue PrEP; proteinuria prevalence and fracture risk; cannabis, cocaine, and inflammation in people living with HIV.